This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3…
- Investigator
- Dina Khalaf
- Ages
- 18 Years - N/A
- Sexes
- All